{"id":62792,"date":"2026-03-16T13:06:35","date_gmt":"2026-03-16T12:06:35","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/korsana-biosciences-appoints-mark-vignola-ph-d-as-chief-financial-officer\/"},"modified":"2026-03-16T13:06:35","modified_gmt":"2026-03-16T12:06:35","slug":"korsana-biosciences-appoints-mark-vignola-ph-d-as-chief-financial-officer","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/korsana-biosciences-appoints-mark-vignola-ph-d-as-chief-financial-officer\/","title":{"rendered":"Korsana Biosciences Appoints Mark Vignola, Ph.D., as Chief Financial Officer"},"content":{"rendered":"
\n

\nProven leader with over 15 years of experience successfully implementing financial and operational strategies across biotech industry<\/i><\/p>\n

WALTHAM, Mass.–(BUSINESS WIRE)–Korsana Biosciences, Inc. (\u201cKorsana\u201d or the \u201cCompany\u201d), a biotechnology company discovering and developing novel therapies to reduce the burden of neurodegenerative diseases, today announced that Mark Vignola, Ph.D., has joined as Chief Financial Officer (CFO). Dr. Vignola brings extensive leadership experience in corporate finance across the biotech industry.<\/p>\n

<\/a>
<\/a><\/p>\n

\n\u201cWe are excited to welcome Mark as our Chief Financial Officer, with his extensive experience as a strategic financial leader to biotech companies and strong track record of advancing companies through major inflection points,\u201d said Jonathan Violin, Ph.D., President and Chief Executive Officer of Korsana. \u201cMark is an outstanding addition to the executive team and will undoubtedly help our growing organization advance our pipeline of potential best-in-class therapies for neurodegenerative disorders.\u201d<\/p>\n

\n\u201cI am thrilled to join Korsana and help support our mission to deliver best-in-class treatment options to patients who deserve better,\u201d said Dr. Vignola. \u201cWe are well positioned to advance the next generation of therapies for Alzheimer\u2019s disease and other neurodegenerative disorders, with a clear path to long-term growth and value creation. I look forward to partnering with the executive team and the Board of Directors.\u201d<\/p>\n

\nDr. Vignola brings over 15 years of experience and is a proven leader in implementing financial and operational strategies to create long-term value for shareholders across the biotech industry. He most recently served as the CFO of Terns Pharmaceuticals, where he led the company\u2019s crossover financing, initial public offering (IPO), and multiple follow-on offerings. Prior to joining Terns, he was CFO at Applied Therapeutics, a clinical-stage biopharmaceutical company where he led several financing rounds. Earlier in his career, Dr. Vignola was Head of Corporate Development and Investor Relations at Intercept Pharmaceuticals and a biotechnology equity research analyst at Needham & Company. Dr. Vignola earned his B.S. in Biology from Boston College and his Ph.D. in Molecular Genetics and Microbiology from Duke University.<\/p>\n

\nAbout Korsana Biosciences<\/b><\/p>\n

\nKorsana Biosciences was founded to reduce the burden of neurodegenerative diseases for patients and caregivers. In partnership with Paragon Therapeutics, Korsana has developed Therapeutic Targeting (THETA\u2122), a novel blood-brain barrier-penetrant shuttle platform designed to enable dramatically higher drug concentration inside the brain and overcome the limitations of earlier shuttle technologies. Korsana is advancing a pipeline of innovative THETA-enabled therapies for neurodegenerative diseases, starting with KRSA-028 for the treatment of Alzheimer\u2019s disease. For more information, please visit www.korsana.com<\/a>.<\/p>\n

Contacts<\/b> <\/p>\n

\nFor Investor and Media Inquiries:
\n
Argot Partners
\n
212-600-1902
\n
korsana@argotpartners.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Proven leader with over 15 years of experience successfully implementing financial and operational strategies across biotech industry WALTHAM, Mass.–(BUSINESS WIRE)–Korsana Biosciences, Inc. (\u201cKorsana\u201d or the \u201cCompany\u201d), a biotechnology company discovering and developing novel therapies to reduce the burden of neurodegenerative diseases, today announced that Mark Vignola, Ph.D., has joined as Chief Financial Officer (CFO). Dr. … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-62792","6":"format-standard","7":"category-industry"},"yoast_head":"\nKorsana Biosciences Appoints Mark Vignola, Ph.D., as Chief Financial Officer - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/korsana-biosciences-appoints-mark-vignola-ph-d-as-chief-financial-officer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Korsana Biosciences Appoints Mark Vignola, Ph.D., as Chief Financial Officer - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Proven leader with over 15 years of experience successfully implementing financial and operational strategies across biotech industry WALTHAM, Mass.–(BUSINESS WIRE)–Korsana Biosciences, Inc. (\u201cKorsana\u201d or the \u201cCompany\u201d), a biotechnology company discovering and developing novel therapies to reduce the burden of neurodegenerative diseases, today announced that Mark Vignola, Ph.D., has joined as Chief Financial Officer (CFO). Dr. ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/korsana-biosciences-appoints-mark-vignola-ph-d-as-chief-financial-officer\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-16T12:06:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20260316391631\/en\/2747152\/22\/Korsana_Logo_Color_RGB.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/korsana-biosciences-appoints-mark-vignola-ph-d-as-chief-financial-officer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/korsana-biosciences-appoints-mark-vignola-ph-d-as-chief-financial-officer\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Korsana Biosciences Appoints Mark Vignola, Ph.D., as Chief Financial Officer\",\"datePublished\":\"2026-03-16T12:06:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/korsana-biosciences-appoints-mark-vignola-ph-d-as-chief-financial-officer\\\/\"},\"wordCount\":440,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/korsana-biosciences-appoints-mark-vignola-ph-d-as-chief-financial-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260316391631\\\/en\\\/2747152\\\/22\\\/Korsana_Logo_Color_RGB.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/korsana-biosciences-appoints-mark-vignola-ph-d-as-chief-financial-officer\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/korsana-biosciences-appoints-mark-vignola-ph-d-as-chief-financial-officer\\\/\",\"name\":\"Korsana Biosciences Appoints Mark Vignola, Ph.D., as Chief Financial Officer - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/korsana-biosciences-appoints-mark-vignola-ph-d-as-chief-financial-officer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/korsana-biosciences-appoints-mark-vignola-ph-d-as-chief-financial-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260316391631\\\/en\\\/2747152\\\/22\\\/Korsana_Logo_Color_RGB.jpg\",\"datePublished\":\"2026-03-16T12:06:35+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/korsana-biosciences-appoints-mark-vignola-ph-d-as-chief-financial-officer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/korsana-biosciences-appoints-mark-vignola-ph-d-as-chief-financial-officer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/korsana-biosciences-appoints-mark-vignola-ph-d-as-chief-financial-officer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260316391631\\\/en\\\/2747152\\\/22\\\/Korsana_Logo_Color_RGB.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260316391631\\\/en\\\/2747152\\\/22\\\/Korsana_Logo_Color_RGB.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/korsana-biosciences-appoints-mark-vignola-ph-d-as-chief-financial-officer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Korsana Biosciences Appoints Mark Vignola, Ph.D., as Chief Financial Officer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Korsana Biosciences Appoints Mark Vignola, Ph.D., as Chief Financial Officer - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/korsana-biosciences-appoints-mark-vignola-ph-d-as-chief-financial-officer\/","og_locale":"en_US","og_type":"article","og_title":"Korsana Biosciences Appoints Mark Vignola, Ph.D., as Chief Financial Officer - Pharma Trend","og_description":"Proven leader with over 15 years of experience successfully implementing financial and operational strategies across biotech industry WALTHAM, Mass.–(BUSINESS WIRE)–Korsana Biosciences, Inc. (\u201cKorsana\u201d or the \u201cCompany\u201d), a biotechnology company discovering and developing novel therapies to reduce the burden of neurodegenerative diseases, today announced that Mark Vignola, Ph.D., has joined as Chief Financial Officer (CFO). Dr. ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/korsana-biosciences-appoints-mark-vignola-ph-d-as-chief-financial-officer\/","og_site_name":"Pharma Trend","article_published_time":"2026-03-16T12:06:35+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20260316391631\/en\/2747152\/22\/Korsana_Logo_Color_RGB.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/korsana-biosciences-appoints-mark-vignola-ph-d-as-chief-financial-officer\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/korsana-biosciences-appoints-mark-vignola-ph-d-as-chief-financial-officer\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Korsana Biosciences Appoints Mark Vignola, Ph.D., as Chief Financial Officer","datePublished":"2026-03-16T12:06:35+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/korsana-biosciences-appoints-mark-vignola-ph-d-as-chief-financial-officer\/"},"wordCount":440,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/korsana-biosciences-appoints-mark-vignola-ph-d-as-chief-financial-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260316391631\/en\/2747152\/22\/Korsana_Logo_Color_RGB.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/korsana-biosciences-appoints-mark-vignola-ph-d-as-chief-financial-officer\/","url":"https:\/\/pharma-trend.com\/en\/korsana-biosciences-appoints-mark-vignola-ph-d-as-chief-financial-officer\/","name":"Korsana Biosciences Appoints Mark Vignola, Ph.D., as Chief Financial Officer - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/korsana-biosciences-appoints-mark-vignola-ph-d-as-chief-financial-officer\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/korsana-biosciences-appoints-mark-vignola-ph-d-as-chief-financial-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260316391631\/en\/2747152\/22\/Korsana_Logo_Color_RGB.jpg","datePublished":"2026-03-16T12:06:35+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/korsana-biosciences-appoints-mark-vignola-ph-d-as-chief-financial-officer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/korsana-biosciences-appoints-mark-vignola-ph-d-as-chief-financial-officer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/korsana-biosciences-appoints-mark-vignola-ph-d-as-chief-financial-officer\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20260316391631\/en\/2747152\/22\/Korsana_Logo_Color_RGB.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20260316391631\/en\/2747152\/22\/Korsana_Logo_Color_RGB.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/korsana-biosciences-appoints-mark-vignola-ph-d-as-chief-financial-officer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Korsana Biosciences Appoints Mark Vignola, Ph.D., as Chief Financial Officer"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62792","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=62792"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62792\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=62792"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=62792"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=62792"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}